Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1899 1
1902 1
1942 1
1945 1
1948 1
1951 1
1954 1
1955 1
1960 1
1965 1
1970 3
1971 4
1972 4
1973 5
1974 1
1976 3
1977 3
1978 5
1979 2
1980 5
1981 4
1982 4
1983 8
1984 10
1985 9
1986 15
1987 9
1988 4
1989 6
1990 10
1991 8
1992 8
1993 14
1994 7
1995 10
1996 11
1997 9
1998 9
1999 10
2000 15
2001 16
2002 20
2003 20
2004 33
2005 22
2006 29
2007 21
2008 29
2009 43
2010 40
2011 36
2012 44
2013 54
2014 42
2015 46
2016 52
2017 51
2018 58
2019 64
2020 67
2021 84
2022 75
2023 68
2024 86
2025 104
2026 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,302 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach AE, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW. Herrera AF, et al. N Engl J Med. 2024 Oct 17;391(15):1379-1389. doi: 10.1056/NEJMoa2405888. N Engl J Med. 2024. PMID: 39413375 Free PMC article. Clinical Trial.
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Sehn LH, et al. Among authors: herrera af. J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6. J Clin Oncol. 2020. PMID: 31693429 Free PMC article. Clinical Trial.
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Locke FL, et al. Among authors: herrera af. Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2. Lancet Oncol. 2019. PMID: 30518502 Free PMC article. Clinical Trial.
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. Neelapu SS, et al. Among authors: herrera af. Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893. Blood. 2023. PMID: 36821768 Free PMC article.
Urinary Catheter Management.
Fletke KJ, Jeong DH, Herrera AV. Fletke KJ, et al. Among authors: herrera av. Am Fam Physician. 2024 Sep;110(3):251-258. Am Fam Physician. 2024. PMID: 39283848 Review.
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, Thieblemont C, Ursu R, Bartlett N, Nachar V, Weiss J, Osterson J, Patel K, Brody J, Abramson JS, Lunning M, Shah NN, Ayed A, Kamdar M, Parsons B, Caimi P, Flinn I, Herrera A, Sharman J, McKenna M, Armand P, Kahl B, Smith S, Zelenetz A, Budde LE, Hutchings M, Phillips T, Dickinson M. Crombie JL, et al. Among authors: herrera a. Blood. 2024 Apr 18;143(16):1565-1575. doi: 10.1182/blood.2023022432. Blood. 2024. PMID: 38252906 Free article.
Skin immune-mesenchymal interplay within tertiary lymphoid structures promotes autoimmune pathogenesis in hidradenitis suppurativa.
Yu WW, Barrett JNP, Tong J, Lin MJ, Marohn M, Devlin JC, Herrera A, Remark J, Levine J, Liu PK, Fang V, Zellmer AM, Oldridge DA, Wherry EJ, Lin JR, Chen JY, Sorger P, Santagata S, Krueger JG, Ruggles KV, Wang F, Su C, Koralov SB, Wang J, Chiu ES, Lu CP. Yu WW, et al. Among authors: herrera a. Immunity. 2024 Dec 10;57(12):2827-2842.e5. doi: 10.1016/j.immuni.2024.11.010. Immunity. 2024. PMID: 39662091 Free PMC article.
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF. Advani RH, et al. Among authors: herrera af. Blood. 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178. Blood. 2021. PMID: 33827139 Free PMC article. Clinical Trial.
1,302 results